BC031781 Inhibitors
Chemical inhibitors of BC031781 can interfere with its activity through various molecular mechanisms. Staurosporine, a potent protein kinase inhibitor, can inhibit the kinase activity of BC031781 by competing with ATP for the binding site within the kinase domain. This competition prevents phosphorylation events that BC031781 is responsible for catalyzing. Similarly, Wortmannin and LY294002, both inhibitors of phosphoinositide 3-kinases (PI3K), can diminish the activity of BC031781 by reducing the levels of PIP3, a critical secondary messenger in many signaling pathways. Since PIP3 production is essential for the function of a variety of proteins, the reduction of this molecule can lead to a decrease in BC031781 activity if it is PI3K-dependent.
Additionally, Rapamycin, an mTOR pathway inhibitor, can suppress the activity of BC031781 by blocking mTOR signaling, which may be necessary for BC031781's function. MEK inhibitors such as PD98059 and U0126 can prevent the activation of ERK, a protein downstream of MEK in the MAPK pathway, potentially leading to the inhibition of BC031781 if it relies on this pathway for activation. SB203580, a p38 MAP kinase inhibitor, and SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, can also reduce BC031781 activity by inhibiting their respective kinases, which could be integral to BC031781's function. Furthermore, EGFR inhibitors Gefitinib and Erlotinib, as well as Lapatinib, which inhibits both EGFR and HER2 tyrosine kinases, can impede the function of BC031781 by blocking the kinase activity of these receptors, assuming BC031781's activity is associated with EGFR or HER2 signaling. Lastly, Triciribine, which inhibits Akt, can decrease the activity of BC031781 if it is dependent on Akt-mediated signaling by preventing the activation of downstream proteins necessary for BC031781's function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Since BC031781 is a kinase, this chemical can inhibit its enzymatic activity by competing with ATP for binding to the kinase domain, thereby preventing phosphorylation events that BC031781 would normally catalyze. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of phosphoinositide 3-kinases (PI3K). BC031781, if functioning downstream of PI3K, would be inhibited by Wortmannin as it would prevent the production of PIP3, a critical secondary messenger that may be necessary for BC031781’s activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, like Wortmannin. It inhibits the activity of PI3K, leading to a decrease in PIP3 levels, which could be critical for the activation or function of BC031781, thereby functionally inhibiting BC031781 by reducing its activating signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. If BC031781 is involved in the mTOR signaling pathway, Rapamycin can inhibit this pathway and thus inhibit the activity of BC031781 by preventing the downstream signaling required for its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which functions upstream of ERK in the MAPK pathway. Inhibition of MEK prevents the activation of ERK, which may be necessary for BC031781 activity, thus functionally inhibiting BC031781 by blocking its necessary signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also a MEK inhibitor and operates similarly to PD98059. By inhibiting MEK, U0126 can prevent the activation of downstream ERK, which could be essential for the functional activity of BC031781, resulting in its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Inhibition of p38 MAPK could lead to a decrease in BC031781 activity if BC031781 requires p38 MAPK signaling for its function, thereby functionally inhibiting BC031781 by blocking necessary activation signals. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If BC031781's activity is JNK-dependent, inhibition of JNK by SP600125 would lead to functional inhibition of BC031781 by preventing its activation or the activation of proteins that are essential for BC031781's function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. BC031781, if it operates downstream of or in conjunction with EGFR signaling, would be functionally inhibited by Gefitinib as it would block the tyrosine kinase activity of EGFR necessary for the activation or function of BC031781. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, like Gefitinib, is an EGFR inhibitor. It would functionally inhibit BC031781 by blocking EGFR signaling pathways that may be necessary for the activity of BC031781, thus preventing the downstream effects that activate or sustain the function of BC031781. | ||||||